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Abstract: As the survival rate of childhood cancers increases, late effects of the 
treatment are becoming significantly more critical. This study evaluates serum 25 
Hydroxy Vitamin D levels and bone mineral density (BMD) of patients with lymphoma 
and solid tumors. This study included patients diagnosed with cancer in Children's 
Hematology-Oncology Hospital, Ankara, Turkey, between 2004 and 2013. These 
patients were all in remission and completed their treatment. Patient data were 
collected from corresponding medical files. Vitamin D levels, BMD measurements, and 
other laboratory tests were performed prospectively after chemotherapy. The study 
group consisted of 105 patients who completed treatment at least one year ago.  
Overall, 59.6 % of the subjects were found to have vitamin D levels less than 20 ng/mL. 
When the factors affecting vitamin D deficiency were evaluated, there were not any 
factors related to vitamin D deficiency. However, a positive correlation was observed 
in the blood sampling time. Namely, test results are taken in the summer months (April-
September) were higher. In our study, bone mineralization disorder (low BMD) was 
found in 44.4% of the patients. Bone health was significantly affected in children who 
recovered from cancer. Physicians who assess these children who recovered from 
cancer must pay necessary attention to these patients' nutrition, vitamin 
supplementations, and physical activities from the start of diagnosis and continued 
follow-up in terms of possible complications. 
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INTRODUCTION 
 The survival rate in childhood cancers has significantly increased with 
chemotherapy (CT), radiotherapy (RT), and intensive care. As the survival rate 
increases, the late effects of treatment are becoming more critical. They may occur 
months or years after the treatment. As children's growth and development process 
continue, they become more susceptible to these late effects. These effects may vary 
depending on the tumor itself, the treatment regimen (surgery, CT, and RT), the age 
at diagnosis and treatment, and the time elapsed in remission. Several earlier studies 
have noted that survivors of pediatric cancers have a higher risk of vitamin D 
insufficiency or deficiency. This risk depends on the tumor itself, treatment regimens, 
poor nutrition. (Andıran et al., 2012; Choudhary et al., 2013; Sinha et al., 2011; 
Simmons et al., 2011; Rossen et al., 2013). However, these studies targeted patients 
that recovered from leukemia, not solid tumors and lymphoma. 
 Earlier studies have noted that bone mineral density typically decreases in 
patients undergoing cancer treatment (Sala et al., 2007). Osteopenia may also occur 
during diagnosis due to increased metabolism, the release of tumor cytokines, and a 
change in bone mineralization density. During the treatment period, corticosteroids 
Medical Laboratory Technology Journal  
 
 Available online at : http://ejurnal-analiskesehatan.web.id 
ISSN 2461-0879 
 




7 (2), 2021, 174-181 
Medical Laboratory Technology Journal | 175 
 
Copyright © 2021, MLTJ, ISSN 2461-0879 
 
therapy, low levels of physical activity, and poor nutrition significantly increase 
osteoporosis and fracture risk in patients who are already osteopenic. (Sala et al., 
2007).  There have been studies of vitamin D levels in patients recovering from 
leukemia, and there have been studies of BMD in children with lymphoma. However, 
to our knowledge, there have been no studies in children with lymphoma and solid 
tumor after completion of chemotherapy. Thus, our study aimed to evaluate the levels 
of 25-hydroxy Vitamin D (vitamin D) and bone mineral density (BMD) of children with 
lymphoma and solid tumors after completing chemotherapy. 
 
MATERIALS AND METHODS 
 Patients diagnosed with lymphoma and solid tumor in Children's Hematology-
Oncology Hospital, Ankara, Turkey, between 2004 and 2013 were included in the 
study. They were all in remission and completed the treatment at least one year ago. 
Patient data on age, gender, primary diagnosis, treatment details were collected from 
corresponding medical files. Vitamin D levels, BMD measurements, and other 
laboratory tests were performed prospectively after treatment. Before starting the 
study, approval was obtained from Ankara Childrens' Hematology and Oncology 
hospital ethics committee (Date: 06.06.2013, Decision No: 158). The subjects were 
included in the study after verbal consent was obtained from those who accepted to 
be included and from their families when they were invited to participate in the study. 
 The data collection process recorded sex, age, diagnosis, stage, diagnosis 
age, treatment, chemotherapy, and radiotherapy information of all patients included in 
the study. Chemotherapeutics and their total doses were calculated during the 
treatment period. Radiotherapy doses and regions were recorded in patients receiving 
radiotherapy. Bone mineral density (BMD) was measured from the lumbar region (L2-
L4) by Dual Energy X-Ray Absorptiometry (DEXA) using the Hologic QDR-4500A (S / 
N 45780) ® computerized densitometry. Results were reported as BMD (g / cm2). 
According to normal BMD values , deviations were expressed as Z-score calculated 
according to a healthy control group of the same age and sex in children. Bone mineral 
density Z-score lower than -2.5 standard deviation (SD) is considered osteoporosis, 
and Z-score was between -1-2.5 SD is considered osteopenia. 
 The venous blood sample taken in the routine follow-up examinations was 
used in laboratory investigations;  Serum Ca, P, ALP, PTH-intact tests were studied in 
the central laboratory to evaluate the metabolism of vitamin D. Ca, P, ALP were 
studied by colorimetric method (Beckman Coulter) ® AU-680 autoanalysers. Serum 
PTH chemiluminescence was measured using immunometric method (Beckman 
Coulter) ® UniCel DxI 800 with autoanalysers. Plasma Vitamin D levels were studied 
using MS / MS (Agilent Technologies) ® methods.  The effects of all these data on 
vitamin D and bone mineralization levels were investigated. 
 SPSS did a statistical analysis of the data for Windows (version 11.5). In the 
two-category comparisons, the Student t-test was used for the variables with normal 
distribution. For the categorical data, the Chi-Square test was applied in the relations. 
In addition, Pearson and Spearman Rank correlation analyses were used to evaluate 
the relationships between the variables. The statistical significance limit of the study 
was accepted as 0.05. 
 There were 105 patients with lymphoma and solid tumors in this study who 
were in remission after cancer treatment. The mean age of the patients at the time of 
diagnosis was 6.77 ± 4.51 years (6 months-19 years). The mean follow-up period was 
4.76 ± 3.00 years (1.5-13 years). The follow-up period after treatment was 3.56 ± 2.76 
years (1-12.5 years). The distribution of patients in terms of diagnosis is as follows; 45 
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patients were diagnosed with lymphoma, and 60 patients were diagnosed with solid 
tumor. There was Hodgkin lymphoma in 28 patients, Non-Hodgkin Lymphoma in 19 
patients, Wilms tumor in 19 patients, central nervous system tumors in 12 patients,   
rhabdomyosarcoma in 8 patients, neuroblastoma in 6 patients, and  13 patients with 
other tumor types.  There were 67 female and 38 male patients. At the time of 
diagnosis, the patients were divided into two groups. Patients with stage 1, 2, and non-
metastatic stages are considered in the early stage; stages 3, 4, and metastatic 
patients were evaluated as the advanced stage. 47.6% (n= 39) of the patients were in 
the early stage group and 52.4% (n= 43) were in the advanced stage group. When the 
time of blood sampling was evaluated, it was observed that in 53.8% of the patients 
(n= 56), the blood sample was taken in winter months (October-March), and in 46.2% 
of the patients (n= 49), it was taken in summer months (April-September). 
Demographic data of patients are summarized in Table 1. 
 
Table 1. General Features of the Study Population (n= 105). 
Male 67 
Female 38 
Age [year, mean±SD, (range)] 
At the time of diagnosis 
At the time of study 
 
6.77 ± 4.51 (6 months-19 years) 
11.82 ± 5.10 (3-28 years) 
Follow up period after treatment 
[years, mean±SD, (range)] 
4.76 ± 3.00 (1.5-13 years) 
Stage 
1 and 2 (early stages)  
3 and 4 (advanced stages)  






















Vitamin D Results: The mean of vitamin D results was 18.40 ± 38.99 ng/ml (4-56 
ng/ml). Vitamin D values were found to be low (<15 ng/ml) in 31 (28.4%) patients. 
Vitamin D values were found to be insufficient (15-20 ng/ml) in 34 (31.2%) patients. 
Vitamin D values were normal (> 20 ng/ml) in 40 (36.7%) patients as shown in Table 
2.  The mean Ca levels of all patients were 9.88 ± 0.47 mg/dl (8.70-10.80 mg/dl), the 
mean of P values were 4.52 ± 0.81 mg/dl (2.20-6.60 mg/dl), the mean ALP values 
were 229.07 ± 99.26 U / L (90-528 U/L).  
 PTH values were 45.85 ± 20.84 pg/ml (13.20-133 pg/ml). PTH elevation was 
not observed in patients whose Vitamin D levels were lower than 20. When the factors 
affecting vitamin D deficiency were evaluated; age, gender, use of radiotherapy and 
chemotherapy, tumor type were not correlated with the level of vitamin D.  While 
vitamin D measurements were low in winter months (October-March), it was observed 
that tests in summer were higher (p<0.05) than any other season. A detailed 
presentation of vitamin D status for 105 patients is summarized in Table 2. 
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Table 2. Detailed Analysis of Vitamin D Status for 105 Patients. 
 Deficiency 
(Vit. D < 15 ng/ml) 
No. of pts (%) 
Insufficiency 
(Vit. D :15-20 ng/ml) 
No. of pts (%) 
Sufficiency 
(Vit. D > 20 ng/ml) 
No. of pts (%) 
Age 
<5 years 
   5-10 years 














   male 












with RT   
Patients not 















   Cisplatin 














    Winter 











    Lymphoma 











    Early 











Bone Mineral Density Results: The bone mineral density of the patients was 
evaluated with Dexa in 99 children. Z-scores of the patients according to age was 
corrected using the oxology 2014 package program. The mean of the DEXA z-score 
was (-0.59) ± 1.25 [(-3.80) -3.08], and the mean BMD (g / cm2) was 0.641 ± 0.168 
(0.399-1.053). Out of 99 patients, 55 patients (55.6%) are diagnosed with a normal 
BMD z-score, 41 (41.4%) patients had a low BMD z-score [(-1.00) - (- 2.5)] 
(osteopenia), and 3 patients (3.0%) were found to be severe [-2.5 and under] 
(osteoporosis). The results are summarized in Table 3. 
 
Table 3. BMD Z-score Analysis on Our Patient Set. 
 
 
Normal (>-1) Osteopenia (-1, - 2.5) Osteoporosis (<-2.5) 
No of Patients / 
Percentage 
55 / 55.6 41 / 41.4 3 / 3 
Mean BMD (g / 
cm2) level 
0.641 ± 0.168 (0.399-1.053) 
Mean DEXA z-
score level 
(-0.59) ± 1.25 [(-3.80) -3.08] 
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 Children are more sensitive to the late effects of cancer treatment as they are 
in growth and development. These effects include endocrine system problems, 
metabolic problems, pulmonary and cardiovascular problems, learning difficulties, 
psychological problems, and secondary cancer development.  
 Late side effects of the endocrine system are more common, as noted in 
many earlier studies (Bhatia et al., 2006; Cohen, 2003; Bircan, 2003; Nandagopal et 
al., 2008). Changes in bone mineral density, growth retardation, malnutrition, and 
obesity are common problems in cancer treatment children. 25-OH-vitamin D is the 
major circulating form of vitamin D, and its analysis is recommended to show vitamin 
D status. In this study, we evaluated bone mineral density levels and 25 OH-vitamin 
D status in children with lymphoma and solid tumors after completion of therapy. 
 In our study, vitamin D deficiency and deficiency rate was found to be higher 
when compared with the average population in Turkey (Bircan et al. 2003, Andıran et 
al., 2012). The prevalence of vitamin D deficiencies in the average population is 14-
49% in Turkey. In a recent study by Andıran N. et al., 440 children were evaluated in 
Ankara between the ages of 0-16, and 40% of the cases were observed to have 
vitamin D levels below 20 ng/ml (5). Compared with healthy children, the rate of low 
vitamin D levels was significantly higher in our study group with pediatric cancer. 
59.6% of the subjects were found to have vitamin D levels less than 20 ng/mL. 
 In a recent study by Choudhary et al., 484 patients were evaluated after 
cancer treatment, and a vitamin D deficiency rate was determined in 29% of the 
patients. In this study, vitamin D deficiency was associated with puberty (Tanner phase 
3-5) and race (Non-Hispanic African origin, Asian origin, Hispanic origin). BMI, gender, 
diagnosis, RT, and steroid use were not associated with vitamin D levels (6). 
 In another study, Sinha et al. reported that vitamin D deficiency was 
significantly higher in the patient group (21.3%) of those who received cancer 
treatment than in the control group (3.3%). Age, black ethnic origin, winter season, 
and cancer disease were reported as risk factors in the study (Sinha et al., 2011). In 
another study by Simmons JH et al., 78 patients were evaluated after the treatment of 
acute lymphoblastic leukemia (ALL), and 12% of them were found to be vitamin D 
deficient (<15 ng / ml). In contrast, 53 of them were found to be vitamin D insufficient 
(15-30 ng/ml). Increasing vitamin D levels at a young age, increased dietary vitamin D 
intake increased vitamin D support. Increased exposure to sunlight was observed to 
have a positive effect, while treatment type, race, sex, diagnosis, time after diagnosis, 
and BMI were found not to affect the outcome (Simmons JH et al., 2011).  
 Rossen et al. reported that the mean vitamin D value was 29.8 ng/ml; it was 
observed that vitamin D deficiency was 14.4%, and failure was 39.3% during the post-
remission study. The decrease in time was found to be 11.4%, and this figure was 
found to be statistically significant (p<0.0001). The results of earlier vitamin D 
deficiency studies are summarized in Table 4.  To our knowledge, in our study, the 
lowest vitamin D levels were determined in children with cancer compared to other 
previously published studies from different countries.  Another interesting finding in 
our study is that vitamin D deficiency was unrelated to the treatment content, steroid 
usage, cumulative chemotherapy dosage, and radiotherapy use.  
 In our study, the rate of osteopenia was 41.4%, and the osteoporosis rate 
was 3.0%, as illustrated in Table-3. The low bone mineral density ratio was 
approximately 45% in total. In studies, this rate varies concerning diagnosis, treatment, 
and time after treatment. Kaste et al. reported a low bone mineral density rate of 26% 
with quantitative computed tomography in 99 patients with a mean duration of 7.2 
years. Othman et al. reported that the rate of osteopenia was 26%, and the 
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osteoporosis rate was 16% in 31 patients with Wilms tumor (Othman et al., 2002). Sala 
et al. reported that the rate of osteopenia is 45% in patients with lymphoma whose 
treatment was terminated at least one year ago (Sala et al., 2007). Odame et al. 
reported the rate of osteopenia as 44% in 25 patients with brain tumors with a mean 
follow-up of 7.4 years (Odame et al., 2006).  
 Maniadaki et al. reported, 17 (group 1) at the beginning of the treatment, 16 
(group 2) at the initiation of KT, and ten patients with ALL (10 patients) who had been 
treated at the end of the study, the BMD z score was -0.74 ± 0.32, -1.59 ± 0.24, -2.03± 
0.27 respectively (Maniadaki et al., 2006). They found a statistically significant 
difference between groups 1 and 3. The ratio of patients with BMD <- two was reported 
to be 17% in group 1, 25% in group 2, and 50% in group 3. Kaste et al. reported that 
the rate of osteoporosis was 44.3%, and the rate of osteopenia was 41.4% in 70 ALL 
patients with a mean follow-up of 4.9 ± 2.5 years (Kaste et al., 2001). In the analysis 
of risk factors on BMD, daily calcium intake yielded significant results. The duration of 
treatment, cranial radiotherapy, and cumulative steroid dose did not significantly affect 
BMD levels. These studies show that the rate of decrease in BMD levels increases as 
the duration of treatment increases and it reaches the highest rate at the end of 
treatment. In our study, DEXA evaluation of patients was performed after the 
completion of treatment. The DEXA measurements of the patients were not taken 
before the treatment. Thus, it was not possible to compare the changes at the end of 
the diagnosis and treatment. However, literature in children and adults shows that 
oncologic treatment increases BMD. Furthermore, most of these studies describe the 
low rates of BMD in different stages of treatment protocols (Odame et al., 2006; 
Maniadaki et al., 2006). 
 When the literature is reviewed, it is seen that a low BMD ratio has been 
reported in a wide range from 25% to 85% (Kaste et al., 2001; Bechard et al., 2015). 
In the literature, the rate of BMD in children with cancer was mainly investigated in 
patients with leukemia. The rate of BMD in these patients varies between 21-85% 
(Kaste et al., 2001; Bechard et al., 2015). The rates in patients with lymphoma and 
solid tumors are between 26-65% (Bechard et al., 2015). In our study, similarly, the 
low BMD rate was found to be 44.4%. Therefore, the results should be evaluated 
carefully. Because it is one of the influential factors in the studies, the methods, 
diagnostic groups, applied treatments, and follow-up periods of BMD vary. In addition, 
vital differences such as nutrition and activity and hereditary factors, which affect BMD, 
have not been addressed in most of these studies. 
 
Table 4. A Comparison of Vitamin D Deficiency in Studies. 
Study  No of subjects Age Vitamin D Deficiency 
Andıran et al., 2012 440 0-16 40% 
Chaudry et al., 2013 484 0-18 29% 
Sinha et al., 2011 61 1.5- 24 21.3% 
Simmons et al., 2011 78 8-21 53% 
Rossen et al., 2013 201 - 53.7% 
Artan et al., 2021 105 0-18 59.6% 
 
 There were some limitations associated with our study. Since we used 
retrospective data on patients' data retrospectively obtained from hospital records of 
our study group, there is a lack of data regarding BMI, social status, time spent under 
daylight, dressing habits, and daily vitamin D intake of children. Vitamin D levels, BMD 
measurements, and other laboratory tests are performed prospectively. The methods, 
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diagnostic groups, applied treatments, and follow-up periods of BMD vary. In addition, 
vital differences such as nutrition and activity and hereditary factors, which affect BMD, 
have not been addressed in most of these studies. Additionally, this is a one-center 
study held in Ankara; thus, it does not reflect the status of all Turkish children. 
 
CONCLUSION 
 In conclusion, vitamin D levels in children with lymphoma and solid tumors 
are markedly lower than healthy children in our country, Turkey. Our study is important 
in terms of reflecting vitamin D status in children with cancer in Turkey. Comparing 
studies investigating vitamin D status in children with cancer, the lowest vitamin D rate 
was found in our study population. It was also noticed that bone strength was 
significantly affected by the children who recovered from cancer. Physicians who 
assess these children who recovered from cancer must pay necessary attention to 
these patients' nutrition, vitamin supplementations, and physical activities from the 
start of diagnosis and continued follow-up in terms of possible complications. 
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